Catapult Capital Management’s Gilead Sciences GILD Stock Holding History

Catapult Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$3.58M	Sell	36,408 -34,392	-49%	-$3.82M	1.35%	16
2015 Q2	$8.29M	Buy	+70,800	New	+$7.74M	1.19%	15
2015 Q1	–	Sell	-81,490	Closed	-$7.68M	–	226
2014 Q4	$7.68M	Buy	+81,490	New	+$8.43M	1.95%	15
2014 Q1	–	Sell	-45,000	Closed	-$3.38M	–	221
2013 Q4	$3.38M	Buy	+45,000	New	+$3.13M	0.81%	39
2013 Q3	–	Sell	-59,778	Closed	-$3.06M	–	262
2013 Q2	$3.06M	Buy	+59,778	New	+$3.12M	1.28%	14

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Catapult Capital Management's GILD Position: Q3 2015 in Review

Catapult Capital Management reduced its Gilead Sciences (GILD) stake by 49% in Q3 2015, selling an estimated $3.82M and leaving 36,408 shares worth $3.58M. The position accounts for 1.35% of the portfolio, ranked #16.

Catapult Capital Management first reported a position in GILD in Q2 2013 and has held it in 5 quarters since. The position peaked at $8.29M in Q2 2015. 1,573 funds tracked by Wall St. Rank hold GILD as of Q3 2015.

Catapult Capital Management held 36,408 shares of Gilead Sciences worth $3.58M as of Q3 2015.
Catapult Capital Management sold 34,392 Gilead Sciences shares in Q3 2015, an estimated $3.82M.
Gilead Sciences made up 1.35% of Catapult Capital Management's portfolio in Q3 2015, its #16 holding.
Catapult Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 5 quarters since.
Catapult Capital Management's Gilead Sciences position peaked at $8.29M in Q2 2015.
1,573 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.